BYBoshen Yang

Boshen Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Boshen Yang has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Amila Kuati

    Department of Rehabilitation, Peking University Third Hospital, Beijing 100191, China

    1 shared publication
  • Changning Hao

    Department of Gerontology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China

    1 shared publication
  • Junli Duan

    Department of Gerontology, Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200082, P. R. China

    1 shared publication
  • Kaifan Niu

    Department of Cardiology, Shanghai Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China

    1 shared publication
  • Liangshi Hao

    Department of Urology, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200011, China

    1 shared publication
  • Wei Liu

    Department of Cardiology, Shanghai Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China

    1 shared publication

Latest Publications

  • Open Access

    Ferroptosis in Septic Cardiomyopathy Is Alleviated by Ondansetron: The Critical Role of the HTR3A-ATF3 Axis in Mitochondrial and Oxidative Homeostasis

    by Xinyun Wang, Yangyi Lin, Wei Liu, Yufeng Wu, Boshen Yang, Yiming Qi, Yipeng Zhang, Yuanyuan Jin, Yuanlong Wang, Kaifan Niu, et al.

    Background: Emerging evidence has established ferroptosis as a vital factor in the pathogenesis of cardiovascular diseases, especially in septic cardiomyopathy (SCM). Meanwhile, ondansetron (OND), a well-established 5-HT3 receptor antagonist, has gained increasing attention for its pleiotropic effects. However, its potential to modulate ferroptosis in the cardiovascular field remains unexplored. This study aims to fill this gap by exploring the potential of OND as an innovative therapeutic intervention for SCM. Methods: This study utilized both in vitro and in vivo models of septic cardiomyopathy (SCM), which was induced by lipopolysaccharide (LPS) stimulation in neonatal rat cardiomyocytes (NRCMs) and C57BL/6 mice. Through RNA sequencing, as well as molecular and functional assessments—including echocardiography and ferroptosis-related measurements—we revealed the anti-ferroptotic effect of ondansetron (OND). Mechanistically, ATF3 was identified as a pivotal regulator, with its overexpression via AAV9 in vivo and ADV in vitro confirming its role in OND-induced cardioprotection. Results: Ondansetron (OND) showed potent anti-ferroptotic effects in both cellular and murine models of septic cardiomyopathy (SCM). Treatment with OND not only improved cardiac performance but also reduced ferroptotic markers, mitigated lipid peroxidation and iron overload, and bolstered antioxidant defense. Notably, OND administration attenuated oxidative and endoplasmic reticulum (ER) stress while restoring mitochondrial integrity. Mechanistically, the anti-ferroptotic activity of OND was mediated through the HTR3A/ATF3 axis: ATF3 overexpression negated OND’s protective effects, while HTR3A antagonism with VUF10166 recapitulated its benefits. Conversely, HTR3A agonism with PBG attenuated ferroptosis resistance, further implicating this pathway as central to OND’s mechanism. Conclusions: This study demonstrated a novel pharmacological role for ondansetron (OND) in attenuating ferroptosis in septic cardiomyopathy (SCM) via the HTR3A/ATF3 signaling pathway. This finding delineates a novel therapeutic avenue and supports the repurposing of OND beyond its traditional antiemetic use to cardiovascular applications.

  • Open Access

    Triclosan exposure exacerbates muscle wasting via senescence and IGF-1 pathway suppression: A combined epidemiological and experimental study

    by Zhenlin Yang, Liangshi Hao, Amila Kuati, Xiang Wang, Ziling Qian, Changning Hao, Junli Duan, Boshen Yang, Yuankang Zhu